Development and characterization of antibody reagents to assess anti-PEG IgG antibodies in clinical samples.

Keywords

Antibody, PEG ratio, Chemistry, Immunoglobulin G, Immunology

References

• Role of the Methoxy Group in Immune Responses to mPEG-Protein ConjugatesMerry R. Sherman, L. David Williams, Monika Sobczyk — 2012
• Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidaseNancy J. Ganson, Susan J. Kelly, Edna Scarlett — 2005
• Monoclonal antibody-based quantitation of poly(ethylene glycol)-derivatized proteins, liposomes, and nanoparticles.Tian‐Lu Cheng, Chiu‐Min Cheng, Bing-Mae Chen — 2005
• The Immunogenicity of Polyethylene Glycol: Facts and FictionHuub Schellekens, Wim E. Hennink, Vera Brinks — 2013
• A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers.Yijuan Liu, Helen Reidler, Jing Pan — 2011
• Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins.Mark G.P. Saifer, L. David Williams, Monika Sobczyk — 2014
• Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patientsJonathan K. Armstrong, Georg Hempel, Susanne Koling — 2007
• Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis.Manfred Kurfürst — 1992
• Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.Boris Gorovits, Eric Wakshull, Renuka Pillutla — 2014
• Ligand Binding Assays in the 21st Century Laboratory: Recommendations for Characterization and Supply of Critical ReagentsDenise M. O’Hara, Valerie Theobald, Adrienne Clements Egan — 2012
• Antigen-specific human polyclonal antibodies from hyperimmunized cattleYoshimi Kuroiwa, Poothappillai Kasinathan, Thillainayagen Sathiyaseelan — 2009
• Emerging PEGylated drugsJung Seok Kang, Patrick P. DeLuca, Kang Choon Lee — 2009
• The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics.C. Simone Fishburn — 2008
• Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipientsMichael S. Hershfield, Nancy J. Ganson, Susan J. Kelly — 2014
• Sensitive quantification of PEGylated compounds by second-generation anti-poly(ethylene glycol) monoclonal antibodies.Yu-Cheng Su, Bing-Mae Chen, Kai‐Hsiang Chuang — 2010
• Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agentsR. Garay, Raafat M. El-Gewely, J. Armstrong — 2012

Cited by

• Development of a Generic Anti-PEG Antibody Assay Using BioScale’s Acoustic Membrane MicroParticle TechnologyHuijin Dong, Johanna Mora, Catherine Brockus — 2015
• Anti-PEG antibody bioanalysis: a clinical case study with PEG-IFN-λ-1a and PEG-IFN-α2a in naive patients.Heather Myler, Matthew Hruska, Subasree Srinivasan — 2015
• Modification with polysialic acid–PEG copolymer as a new method for improving the therapeutic efficacy of proteinsJianrong Wu, Shaozeng Lu, Zhiyong Zheng — 2016
• Liposomal nano-drugs based on amphipathic weak acid steroid prodrugs for treatment of inflammatory diseasesKeren Turjeman, Yechezkel Barenholz — 2016
• A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug SubstanceUma Kavita, Wendy Miller, Qin Ji — 2019
• Product-Related Factors and Immunogenicity of BiotherapeuticsMurli Krishna — 2019
• Immunogenicity Risk Assessment for PEGylated TherapeuticsJohanna Mora, Joleen T. White, Stephen DeWall — 2020
• Development and validation of a novel immunogenicity assay to detect anti-drug and anti-PEG antibodies simultaneously with high sensitivity.Nicoletta Bivi, Craig Swearingen, Travis E. Shockley — 2020
• Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature ReviewChae Sung Lee, Yogesh A. Kulkarni, Vicki Pierre — 2024
• Optimizing Pharmacological and Immunological Properties of Therapeutic Proteins Through PEGylation: Investigating Key Parameters and Their ImpactJoão Gonçalves, Paolo Caliceti — 2024
• Immunogenicity of Therapeutic ProteinsW. Jiskoot, Theo Rispens, G. Kijanka — 2019

Related papers

• A GEOMETRIC MEAN IN THE FURUTA INEQUALITYMasatoshi Fujii, Ritsuo Nakamoto — 2002
• Biological Activities of Rabbit Immunoglobulin M and Immunoglobulin G Antibodies to Pseudomonas aeruginosaAnn B. Bjornson, J. Gabriel Michael — 1970
• Development of serum antibodies of the immunoglobulin G class and subclasses against the capsular polysaccharide of Haemophilus influenzae type b in children and adults with invasive infectionsB A Claesson, Teresa Lagergård, Birger Trollfors — 1988
• An enzyme immunoassay for immunoglobulin M antibodies to Toxoplasma gondii which is not affected by rheumatoid factor or immunoglobulin G antibodiesTsue-Ming Lin, Monroe W. Chin-See, Seymour P. Halbert — 1986
• Effect of anti-immunoglobulin antibodies provides new insights into immune response to HCV.Medhat Haroun — 2005
• Isolation of Porcine Immunoglobulins and Determination of the Immunoglobulin Classes of Transmissible Gastroenteritis Viral AntibodiesLinda J. Saif, Ε. H. Bohl, Rajat Gupta — 1972
• Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates*Paul R. Hinton, Mary G. Johlfs, Joanna M. Xiong — 2004